Naleen Raj Bhandari, Lisa M Hess, Rohan C Parikh, Anthony N Sireci, Peter M Krein, James A Kaye
{"title":"美国晚期/转移性甲状腺髓样癌患者的生物标志物检测","authors":"Naleen Raj Bhandari, Lisa M Hess, Rohan C Parikh, Anthony N Sireci, Peter M Krein, James A Kaye","doi":"10.2217/pme-2022-0050","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To describe real-world testing patterns for <i>RET</i> in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. <b>Materials & methods:</b> The authors performed a retrospective medical record analysis of patients with advanced/metastatic medullary thyroid cancer who initiated systemic therapy between 2013 and 2018. Seventy-five US-based oncologists collected the data using a customized electronic data collection form. <b>Results:</b> A total of 59.6% (121 of 203) of patients underwent testing for <i>RET</i>, and 37.2% (45 of 121) had a <i>RET</i> mutation, of which 55.6% were identified as <i>RET</i> mutation-positive before initial diagnosis. Overall, 90 (44.3%) patients were tested for biomarkers on or after initial diagnosis, with <i>RET</i> being the most tested (95.6%) biomarker. <b>Conclusion:</b> The authors' findings suggest an opportunity to improve testing rates in accordance with treatment guidelines.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"20 2","pages":"131-142"},"PeriodicalIF":1.7000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA.\",\"authors\":\"Naleen Raj Bhandari, Lisa M Hess, Rohan C Parikh, Anthony N Sireci, Peter M Krein, James A Kaye\",\"doi\":\"10.2217/pme-2022-0050\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> To describe real-world testing patterns for <i>RET</i> in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. <b>Materials & methods:</b> The authors performed a retrospective medical record analysis of patients with advanced/metastatic medullary thyroid cancer who initiated systemic therapy between 2013 and 2018. Seventy-five US-based oncologists collected the data using a customized electronic data collection form. <b>Results:</b> A total of 59.6% (121 of 203) of patients underwent testing for <i>RET</i>, and 37.2% (45 of 121) had a <i>RET</i> mutation, of which 55.6% were identified as <i>RET</i> mutation-positive before initial diagnosis. Overall, 90 (44.3%) patients were tested for biomarkers on or after initial diagnosis, with <i>RET</i> being the most tested (95.6%) biomarker. <b>Conclusion:</b> The authors' findings suggest an opportunity to improve testing rates in accordance with treatment guidelines.</p>\",\"PeriodicalId\":19753,\"journal\":{\"name\":\"Personalized medicine\",\"volume\":\"20 2\",\"pages\":\"131-142\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Personalized medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pme-2022-0050\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2022-0050","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA.
Aim: To describe real-world testing patterns for RET in US patients with advanced/metastatic medullary thyroid cancer and determine consistency of real-world testing practices with national guidelines. Materials & methods: The authors performed a retrospective medical record analysis of patients with advanced/metastatic medullary thyroid cancer who initiated systemic therapy between 2013 and 2018. Seventy-five US-based oncologists collected the data using a customized electronic data collection form. Results: A total of 59.6% (121 of 203) of patients underwent testing for RET, and 37.2% (45 of 121) had a RET mutation, of which 55.6% were identified as RET mutation-positive before initial diagnosis. Overall, 90 (44.3%) patients were tested for biomarkers on or after initial diagnosis, with RET being the most tested (95.6%) biomarker. Conclusion: The authors' findings suggest an opportunity to improve testing rates in accordance with treatment guidelines.
期刊介绍：
Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis.
The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
